2024-10-27-PitchBook-PitchBook年三季度医疗技术公共报表和估值指南（英）_8页_1mb

Medtech Q3 2024 Public Comp Sheet Summary

Key Takeaways

Analysts expect mid-single-digit revenue growth in 2025 for most medtech segments, with higher EBITDA and free cash flow growth. Valuations have stabilized in the sector, though consumer health shows slight increases. Tempus AI's IPO performance stands out, with strong post-IPO gains despite overall IPO market challenges.